1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
62E0858126C9ED90F85256F5E007FF082
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/pharma-biotech-co-promotion-alliance-and-relationship-management?opendocument
18
19opendocument
203.80.128.196
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Business Operations Alliances and Partnerships

Pharma & Biotech Co-Promotion Alliance and Relationship Management

DB Image

ID: 4769


Features:

Metrics, Graphics


Pages/Slides: 25


Published: Pre-2013


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER

Non-members: Click here to sign-up for a complimentary tour of
"Pharma & Biotech Co-Promotion Alliance and Relationship Management"


Study Overview
The success of any co-development deal or co-promotion deal hinges on stellar alliance execution and careful relationship management. As partners move through the development of a product and the rollout of marketing activities, high levels of team coordination and flexibility, fair, efficient decision-making processes and adequate resources are vital. Factors influencing these needs can greatly affect how partners perceive progress of alliances and, ultimately, the financial success of partnerships. This document will assist business development executives in pharmaceutical and biotechnology companies by enabling them to benchmark their own tactics and strategies against other top companies.

Key topics

  • Decision Making Process
  • Flexibility
  • Team Coordination
  • Resources

Sample Best Practices
  • Create a clear decision-making process to ensure that project counterparts know the deal’s standing in other company.
  • * One business development director noted that when a decision is needed, he takes a recommendation to his CEO, who either agrees or disagrees with the assessment. That assessment then goes before the company’s board of directors. The entire decision process takes about two days, he said.
  • Periodically re-evaluate the alliance to guarantee that the project is meeting both partners’ expectations.
  • *One executive said generally with a partnership it is important not to get impatient, and he is pleased to say that his counterpart’s company has been patient and wants to understand the situation.
  • Provide adequate personnel after an agreement is reached to sustain the partnership’s vitality.
  • *One business development director noted that the lack of a full-time licensing team at one partner was viewed poorly even though it was known that the partner was interested in the deal.

Methodology
The research for this study came from a Best Practices, LLC consulting project. Originally done for a pharmaceutical client, it was based on interviews and online research from benchmark companies in numerous industries.

Industries Profiled:
Biotech; Pharmaceutical


Companies Profiled:
Atrix; AtheroGenics; Bristol-Myers Squibb; CV Therapeutics; Fujisawa; GlaxoSmithKline; Aderis; Cardiome; Micrologix


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.